«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2024年05期

页码:

831-835

栏目:

综述

出版日期:

2024-10-25

文章信息/Info

Title:

-

作者:

宋新雅¹; 苏小慧¹; 卞士柱³; 丁小涵¹; 2

730000 兰州,甘肃中医药大学第一临床医学院¹
730000 兰州,联勤保障部队第九四〇医院干部病房²
400037 重庆,陆军(第三)军医大学第二附属医院心血管内科³

Author(s):

-

关键词:

肺动脉高压;  吸入投药;  靶向制剂;  心血管疾病

Keywords:

-

分类号:

R452,R543.2

DOI:

10.3877/cma.j.issn.1674-6902.2024.05.033

摘要:

-

Abstract:

-

参考文献/References:

1 Jia Z, Wang S, Yan H, et al. Pulmonary vascular remodeling in pulmonary hypertension^[J]. J Pers Med, 2023, 13(2): 643-649.
2 Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension^[J]. Eur Respir J, 2019, 53(1): 1801913.
3 中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组等. 中国肺动脉高压诊断与治疗指南(2021版)^[J]. 中华医学杂志, 2021, 101(1): 11-51.
4 任成山, 卞士柱, 胡明冬. 肺动脉高压的成因及治疗新理念[J/CD]. 中华肺部疾病杂志(电子版), 2023, 16(1): 1-5.
5 Kovacs G, Olschewski H. The definition of pulmonary hypertension: history, practical implications and current controversies[J]. Breathe(Sheff), 2021, 17(3): 210076.
6 Maron BA, Abman SH, Elliott CG, et al. Pulmonary arterial hypertension: diagnosis, treatment, and novel advances[J]. Am J Respir Crit Care Med, 2021, 203(12): 1472-1487.
7 Otani N, Tomoe T, Kawabe A, et al. Recent advances in the treatment of pulmonary arterial hypertension[J]. Pharmaceuticals(Basel), 2022, 15(10): PMID: 36297387.
8 Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J, 2023, 61(1): 3618-3731.
9 万 钧, 翟振国. 肺动脉高压临床诊治和管理中需要关注的热点问题——基于《2022 ESC/ERS肺动脉高压诊治指南》与《中国肺动脉高压诊断与治疗指南(2021版)》的比较与解读[J]. 中国全科医学, 2023, 26(3): 255-261+267.
10 Olsson KM, Corte TJ, Kamp JC, et al. Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management[J]. Lancet Respir Med, 2023, 11(9): 820-835.
11 Kjellström B, Hjalmarsson C, Kylhammar D, et al. Pulmonary arterial hypertension: assessing risk to improve prognosis[J]. Expert Rev Cardiovasc Ther, 2019, 17(1): 1-2.
12 Chen SY, Li J. Current status and prospects of targeted drug therapy for pulmonary arterial hypertension[J]. N Clin Med(中国临床新医学), 2020, 13(9): 852-858.
13 El-kersh K, Jalil BA. Pulmonary hypertension inhaled therapies: An updated review[J]. Am J Med Sci, 2023, 366(1): 3-15.
14 Mandras S, Kovacs G, Olschewski H, et al. Combination therapy in pulmonary arterial hypertension-targeting the nitric oxide and prostacyclin pathways[J]. J Cardiovasc Pharmacol Ther, 2021, 26(5): 453-462.
15 Zeng C, Liu J, Zheng X, et al. Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension[J]. Respir Res, 2023, 24(1): 263.
16 De Wet CJ, Affleck DG, Jacobsohn E, et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery[J]. J Thorac Cardiovasc Surg, 2004, 127(4): 1058-1067.
17 Ghadimi K, Cappiello J, Cooter-wright M, et al. Inhaled pulmonary vasodilator therapy in adult lung transplant: a randomized clinical trial[J]. JAMA Surg, 2022, 157(1): e215856.
18 Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy(ARIES)study 1 and 2[J]. Circulation, 2008, 117(23): 3010-3019.
19 王 瑞, 武 云. 肺动脉高压靶向药物治疗的研究进展[J]. 医学综述, 2022, 28(9): 1776-1783.
20 Qin YW, Bai Y. Inhaled iloprost for the treatment of primary pulmonary hypertension [J]. Pharm Care & Res, 2006,6: 406-409.
21 Alqarni AA, Aldhahir AM, Bintalib HM, et al. Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review[J]. Front Med(Lausanne), 2023, 10: 1217156.
22 Stollfuss B, Richter M, Drömann D, et al. Digital tracking of physical activity, heart rate, and inhalation behavior in patients with pulmonary arterial hypertension treated with inhaled iloprost: observational study(ventastep)[J]. J Med Internet Res, 2021,23(10): e25163.
23 Waxman A, Restrepo-jaramillo R, Thenappan T, et al. Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study[J]. Eur Respir J, 2023, 61(6): 2202414.
24 Sandifer BL, Brigham KL, Lawrence EC, et al. Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation[J]. J Appl Physiol, 2005, 99(6): 2363-2368.
25 Waxman A, Restrepo-jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease[J]. N Engl J Med, 2021, 384(4): 325-334.
26 Weatherald J, Nathan SD, El-kersh K, et al. Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study[J]. BMJ Open Respir Res, 2024, 11(1): e002116.
27 Jin Q, Chen D, Zhang X, et al. Medical management of pulmonary arterial hypertension: current approaches and investigational drugs[J]. Pharmaceutics, 2023, 15(6): 1579.
28 Kiani A, Omidvar R, Naderi N, et al. The long-term response to treatment with calcium channel blockers in patients with idiopathic pulmonary arterial hypertension[J]. J Tehran Heart Cent, 2023, 18(1): 62-67.
29 Oki T, Ikeda Y, Ishii S, et al. Inhaled nitric oxide for ECPELLA management in fulminant myocarditis complicated with severe right ventricular dysfunction: A case report[J]. J Cardiol Cases, 2022, 26(2): 104-107.
30 王 岩. 吸入性一氧化氮在先心病肺动脉高压患者术后的应用[D]. 山东大学, 2006: 23-42.
31 Benedetto M, Piccone G, Gottin L, et al. Inhaled pulmonary vasodilators for the treatment of right ventricular failure in cardio-thoracic surgery: is one better than the others?[J]. J Clin Med, 2024, 13(2): 564.
32 Pérez-peñate GM, Juliá-serdá G, Galván-fernández H, et al. Safety of inhaled nitric oxide withdrawal in severe chronic pulmonary hypertension[J]. Pulm Circ, 2024,14(1):e12344. oxide[J]. Am J Respir Crit Care Med, 2000, 161(5): 1443-1449.
33 Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review[J]. Jama, 2022, 327(14): 1379-1391.
34 Keshavarz A, Kadry H, Alobaida A, et al. Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension[J]. Expert Opin Drug Deliv, 2020, 17(4): 439-461.
35 Gillies H, Chakinala MM, Dake BT, et al. IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension[J]. Pulm Circ, 2024, 14(1): e12352.
36 Wilkins MR, Mckie MA, Law M, et al. Positioning imatinib for pulmonary arterial hypertension: A phase Ⅰ/Ⅱ design comprising dose finding and single-arm efficacy[J]. Pulm Circ, 2021, 11(4): 20458940211052823.
37 Gillies H, Niven R, Dake BT, et al. AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study[J]. ERJ Open Res, 2023, 9(2): 00433-2022.
38 Galkin A, Sitapara R, Clemons B, et al. Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension[J]. Eur Respir J, 2022, 60(6): 2102356.
39 Kumar S, Biswas L, Pushkaran AC, et al. BMPR2 mutation and clinical response to imatinib in a case of heritable pulmonary arterial hypertension[J]. Pulm Circ, 2024, 14(1): e12335.
40 Frantz RP, Benza RL, Channick RN, et al. TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension[J]. Pulm Circ, 2021, 11(4): 20458940211057071.
41 Kimmig LM, Liao C, Bag R. Ambulatory transition from parenteral prostanoid to inhaled treprostinil in patients with pulmonary arterial hypertension[J]. Lung, 2020, 198(1): 53-58.

备注/Memo

备注/Memo:

基金项目: 军队保健课题基金资助(21BJZ42)
国家自然科学基金项目资助(81901916)
通信作者: 丁小涵, Email: xiaohan-ding@163.com

常用功能

更新日期/Last Update: 2024-10-25